Although T cell receptor (TCR) signals are essential for intrathymic T cell–positive selection, it remains controversial whether they only serve to initiate this process, or whether they are required throughout to promote thymocyte differentiation and survival. To address this issue, we have devised a novel approach to interfere with thymocyte TCR signaling in a developmental stage-specific manner in vivo. We have reconstituted mice deficient for Zap70, a tyrosine kinase required for TCR signaling and normally expressed throughout T cell development, with a Zap70 transgene driven by the adenosine deaminase (ADA) gene enhancer, which is active in CD4+CD8+ thymocytes but inactive in CD4+ or CD8+ single-positive (SP) thymocytes. In such mice, termination of Zap70 expression impaired TCR signal transduction and arrested thymocyte development after the initiation, but before the completion, of positive selection. Arrested thymocytes had terminated Rag gene expression and up-regulated TCR and Bcl-2 expression, but failed to differentiate into mature CD4 or CD8 SP thymocytes, to be rescued from death by neglect or to sustain interleukin 7Rα expression. These observations identify a TCR-dependent proofreading mechanism that verifies thymocyte TCR specificity and differentiation choices before the completion of positive selection.
Skip Nav Destination
Article navigation
3 February 2003
Article|
February 03 2003
Restricting Zap70 Expression to CD4+CD8+ Thymocytes Reveals a T Cell Receptor–dependent Proofreading Mechanism Controlling the Completion of Positive Selection
Xiaolong Liu,
Xiaolong Liu
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Anthony Adams,
Anthony Adams
2Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Kathryn F. Wildt,
Kathryn F. Wildt
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Bruce Aronow,
Bruce Aronow
3Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229
Search for other works by this author on:
Lionel Feigenbaum,
Lionel Feigenbaum
4SAIC Frederick, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702
Search for other works by this author on:
Rémy Bosselut
Rémy Bosselut
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Search for other works by this author on:
Xiaolong Liu
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Anthony Adams
2Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Kathryn F. Wildt
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Bruce Aronow
3Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229
Lionel Feigenbaum
4SAIC Frederick, NCI-Frederick Cancer Research and Development Center, Frederick, MD 21702
Rémy Bosselut
1Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
Address correspondence to Rémy Bosselut, Laboratory of Immune Cell Biology, National Cancer Institute, National Institutes of Health, Building 10, Room 1B43, Bethesda, MD 20892. Phone: 301-402-4849; Fax: 301-402-4844; E-mail: [email protected]
*
Abbreviations used in this paper: ADA, adenosine deaminase; DP, double positive; MFI, mean fluorescence intensity; MHC-p, MHC-peptide complex; SP, single positive.
Received:
September 26 2002
Revision Received:
December 20 2002
Accepted:
December 20 2002
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 197 (3): 363–373.
Article history
Received:
September 26 2002
Revision Received:
December 20 2002
Accepted:
December 20 2002
Citation
Xiaolong Liu, Anthony Adams, Kathryn F. Wildt, Bruce Aronow, Lionel Feigenbaum, Rémy Bosselut; Restricting Zap70 Expression to CD4+CD8+ Thymocytes Reveals a T Cell Receptor–dependent Proofreading Mechanism Controlling the Completion of Positive Selection . J Exp Med 3 February 2003; 197 (3): 363–373. doi: https://doi.org/10.1084/jem.20021698
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement